Part I  General Aspects of Medicinal Chemistry
   Section Editor: Hugo Kubinyi 1

1. A History of Drug Discovery 3
   François Chast
   I. Introduction 4
      A. The renewal of chemistry 4
      B. The dawn of the organic chemistry crosses the birth of biology 5
   II. Two Hundred Years of Drug Discoveries 6
      A. Pain killers: best-sellers and controversies 6
      B. Giving back the heart its youth 10
      C. Fight against microbes and viruses 15
      D. Drugs for immunosuppression 24
      E. Contribution of chemists to the fight against cancer 26
      F. Drugs for endocrine disorders 30
      G. Anti-acid drugs 34
      H. Lipid lowering drugs 35
      I. From neurotransmitters to receptors 37
      J. Drugs of the mind 41
   III. Considerations on Recent Trends in Drug Discovery 49
      A. From genetics to DNA technology 49
      B. Hopes and limits for drug hunting 52
   References 55

2. Medicinal Chemistry: Definitions and Objectives, Drug Activity Phases, Drug Classification Systems 63
   Peter Imming
   I. Definitions and Objectives 63
      A. Medicinal chemistry and related disciplines and terms 63
      B. Drugs and drug substances 64
      C. Stages of drug development 64
   II. Drug Activity Phases 66
      A. The pharmaceutical phase 66
      B. The pharmacokinetic phase 66
5. Drug Targets, Target Identification, Validation and Screening
Kenton H. Zavitz, Paul L. Bartel and Adrian N. Hobden

I. Introduction

II. Improving the Resolution of Disease Etiology
A. Passive immunotherapy

III. Biopharmaceutical Therapies
A. Passive immunotherapy

IV. Drug Target Identification
A. Rare mutations leading to generalized therapies
B. Mining the proteome
C. Yeast two-hybrid systems
D. RNA interference

V. Hit-to-Lead
A. Cell-based screening
B. Intracellular receptors
C. Intracellular enzymes
D. G-protein-coupled receptors
E. Transgenic animals
F. Drug metabolism
G. Toxicology

VI. Clinical Biomarkers

VII. Conclusions

References

Part II Lead Compound Discovery Strategies
Section Editor: John R. Proudfoot

6. Strategies in the Search for New Lead Compounds or Original Working Hypotheses
Camille G. Wermuth

I. Introduction

A. Hits and leads

B. The main hit or lead finding strategies

II. First Strategy: Analog Design
A. Typical examples

B. The different categories of analogs

C. Pros and cons of analog design

III. Second Strategy: Systematic Screening
A. Extensive screening

B. Random screening

C. High-throughput screening

D. Screening of synthesis intermediates

E. New leads from old drugs: The SOSA approach

IV. Third Strategy: Exploitation of Biological Information
A. Exploitation of observations made in humans

B. Exploitation of observations made in animals

C. Exploitation of observations made in the plant kingdom and in microbiology

V. Fourth Strategy: Planned Research and Rational Approaches
A. L-DOPA and parkinsonism
## Contents

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>139</td>
</tr>
<tr>
<td>141</td>
</tr>
<tr>
<td>142</td>
</tr>
<tr>
<td>144</td>
</tr>
</tbody>
</table>

7. High-Throughput Screening and Drug Discovery

John R. Proudfoot

I. Introduction
II. Historical Background
III. From Screen to Lead
   A. Compound collections
   B. Assays
   C. Hit-to-lead process
IV. Examples of Drugs Derived from Screening Leads
   A. Reverse transcriptase inhibitors, nevirapine, efavirenz, and delavirdine
   B. Endothelin antagonists, bosentan, sitaxsentan, edonentan, and ambrisentan
   C. Raf kinase inhibitor, sorafenib
V. Practical Application, Recent Example
   A. IKK inhibitors
VI. Conclusion
References

8. Natural Products as Pharmaceuticals and Sources for Lead Structures

David J. Newman, Gordon M. Cragg and David G. I. Kingston

I. Introduction
II. The Importance of Natural Products in Drug Discovery and Development
   A. The origin of natural products
   B. The uniqueness of the natural products approach
   C. The impact of new screening methods
III. The Design of an Effective Natural-Products-Based Approach to Drug Discovery
   A. Acquisition of biomass
   B. The unexplored potential of microbial diversity
   C. Extraction
   D. Screening methods
   E. Isolation of active compounds
   F. Structure elucidation
   G. Further biological assessment
   H. Procurement of large-scale supplies
   I. Determination of structure–activity relationships
IV. Examples of Natural Products or Analogs as Drugs
   A. Antihypertensives
   B. Anticholesterolemics
   C. Immunosuppressives
   D. Antibiotics
   E. Microbial anticancer agents
   F. Anticancer agents from plants
   G. Anticancer agents from marine organisms
   H. Antimalarial agents
   I. Other natural products
V. Future Directions in Natural Products as Drugs and Drug Design Templates
   A. Introduction
   B. Combinatorial chemistry
   C. Natural products as design templates
   D. Interactions of microbial sources, genomics, and synthetic chemistry
VI. Summary
References
9. Biology Oriented Synthesis and Diversity Oriented Synthesis in Compound Collection Development
Kamal Kumar, Stefan Wetzel and Herbert Waldmann

I. Introduction 187
II. Diversity Oriented Synthesis 188
   A. DOS: Principles 188
   B. DOS of small molecule libraries 188
   C. Applications of DOS libraries 192
III. Biology Oriented Synthesis 194
   A. Introduction 194
   B. The scaffold tree for structural classification of natural products 194
   C. Protein structure similarity clustering 199
   D. BIOS: The combined application of SCONP and PSSC 202
   E. BIOS: Prospects and future directions 205
IV. Conclusion and Outlook 205
References 206

10. In Silico Screening: Hit Finding from Database Mining
Thierry Langer and Sharon D. Bryant

I. Introduction 210
   A. Chemoinformatics in drug discovery 211
   B. What is the difference between a hit and a lead structure? 211
   C. Data mining using chemoinformatics 212
II. Representation of Chemical Structures 212
   A. Structural keys and 1D fingerprints 213
   B. Topological descriptors 213
   C. 3D descriptors 214
   D. Further descriptors 216
III. Data Mining Methods 216
IV. Database Searches 217
   A. Distance and similarity searches 217
   B. 2D database searches 217
   C. 3D database searches 218
V. Applications 218
   A. Ligand-based in silico screening 218
   B. Structure-based in silico screening 219
   C. Assessing affinity profiles using parallel in silico screening 219
   D. Example: Parallel pharmacophore-based virtual screening 219
VI. Conclusion and Future Directions 222
References 222

11. Fragment-Based Drug Discovery
Bennett T. Farmer and Allen B. Reitz

I. Ligand–Protein Interactions: First Principles 228
   A. Binding energy as the sum of the parts 228
   B. Historical development 229
   C. Ligand efficiency 230
II. Status of Late 1990s Drug Discovery in the Pharmaceutical Industry 230
III. What is FBDD? 231
   A. Concept and overview 231
   B. Differences between FBDD and HTS/HTL approaches 233
   C. The role of the medicinal chemist in FBDD 234
### Part III Primary Exploration of Structure–Activity Relationships

**Section Editor: Camille G. Wermuth**

#### 14. Molecular Variations in Homologous Series: Vinylogues and Benzologues

*Camille G. Wermuth*

- I. Homologous Series
  - A. Definition and classification
  - B. Shapes of the biological response curves
  - C. Results and interpretation
- II. Vinylogues and Benzologues
  - A. Applications of the vinylogy principle
  - B. Comments

**References**

#### 15. Molecular Variations Based on Isosteric Replacements

*Paola Ciapetti and Bruno Giethlen*

- I. Introduction
- II. History: Development of the Isosterism Concept
  - A. The molecular number
  - B. The isosterism concept
  - C. The notion of pseudoatoms and Grimm’s hydride displacement law
  - D. Erlenmeyer’s expansion of the isosterism concept
  - E. Isoserism criteria: Present conceptions
  - F. The bioisosterism concept: Friedman’s and Thornber’s definitions
- III. Currently Encountered Isosteric and Bioisosteric Modifications
  - A. Replacement of univalent atoms or groups
  - B. Interchange of divalent atoms and groups
  - C. Interchange of trivalent atoms and groups
  - D. Ring equivalents
  - E. Groups with similar polar effects: functional equivalents
  - F. Reversal of functional groups
- IV. Scaffold Hopping
  - A. Successful examples of serendipitous scaffold hopping
  - B. Scaffold hopping and virtual screening
- V. Analysis of the Modifications Resulting from Isosterism
  - A. Structural parameters
  - B. Electronic parameters
  - C. Solubility parameters
  - D. Anomalies in isosterism
VI. Minor Metalloids-Toxic Isosters 330
   A. Carbon–silicon bioisosterism 330
   B. Carbon–boron isosterism 331
   C. Bioisosteries involving selenium 333
References 334

16. Ring Transformations 343
   Christophe Morice and Camille G. Wermuth
   I. Introduction 343
   II. Analogical Approaches 343
      A. Analogy by ring opening: open-chain analogs 343
      B. Analogy by ring closure 345
      C. Other analogies 349
   III. Disjunctive Approaches 354
      A. Cocaïne-derived local anesthetics 355
      B. Morphinic analgesics 355
      C. Dopamine autoreceptor agonists 355
      D. CCK antagonists 355
   IV. Conjunctive Approaches 356
      A. Dopaminergic antagonists 356
      B. Glutamate NMDA and AMPA receptor antagonists 358
      C. Norfl oxacin analogs 359
      D. Melatonin analogs 360
   V. Conclusion 360
References 360

17. Conformational Restriction and/or Steric Hindrance in Medicinal Chemistry 363
   André Mann
   I. Introduction 363
      A. Theoretical points 364
      B. On constrained analogs 366
      C. On conformational analysis 367
      D. On the natur of Steric effects 368
      E. Rigid compounds and bioavailability 368
   II. Case studies 368
      A. Bradykinin 368
      B. Allylic constraints for inducing conformational rigidity 369
      C. Diversity-Oriented Synthesis 371
      D. Epibatidine bioactive conformation 371
      E. Ligands for the Hepatitis C virus 372
      F. Nociceptin 374
      G. Opioid receptors ligands 374
      H. Peptidomimetics for SH2 domains 375
   III. Summary and Outlook 377
References 378

18. Homo and Heterodimer Ligands the Twin Drug Approach 380
   Jean-Marie Contreras and Wolfgang Sippl
   I. Indroduction 380
   II. Homodimer and Symmetrical Ligands 383
      A. Symmetry in nature 383
      B. Homodimers as receptors ligands 383
      C. Homodimers as enzyme inhibitors 387
D. Homodimers as DNA ligands 390
E. Homodimers of pharmacological interest 390

III. Heterodimer and Dual Acting Ligands 391
A. Hybrid molecules as ligands of two different receptors 391
B. Hybrids as enzymes inhibitors 394
C. Hybrids acting at one receptor and one enzyme 398
D. Other examples of dual acting drugs 400

IV. Binding Mode Analysis of Identical and Non-identical Twin Drugs 401
A. Identical and non-identical twin drugs interacting with two adjacent binding sites located on the same macromolecule 403
B. Identical twin drugs interacting with two similar binding sites located on different monomers of the same macromolecule 405
C. Identical and non-identical twin drugs interacting with two different binding sites located on different macromolecules 408

V. Conclusion 409

References 410

19. Application Strategies for the Primary Structure–Activity Relationship Exploration 415
Camille G. Wermuth

I. Introduction 415
II. Preliminary Considerations 415
III. Hit Optimization Strategies 416
A. Some information about the target is available 417
B. No information about the target is available 418
C. The predominant objective is potency 418
D. The predominant objective is the establishment of SARs 419
E. The predominant objective consists of analog design 422

IV. Application Rules 422
A. Rule number one: the minor modification rule 422
B. Rule number two: the biological logic rule 423
C. Rule number three: the structural logic's rule 424
D. Rule number four: the right substituent choice 424
E. Rule number five: the easy organic synthesis (EOS) rule 425
F. Rule number six: eliminate the chiral centers! 425
G. Rule number seven: the pharmacological logic rule 426

References 426

Part IV Substituents and Functions: Qualitative and Quantitative Aspects of Structure–Activity Relationships
Section Editor: Han van de Waterbeemd 429

20. Substituent Groups 431
Patrick Bazzini and Camille G. Wermuth

I. Introduction 431
II. Methyl Groups 432
A. Effects on solubility 432
B. Conformational effects 434
C. Electronics effects 435
D. Effects on metabolism 437
E. Extensions to other small alkyl groups 440
III. Effects of Unsaturated Groups 441
   A. Vinyl series 442
   B. Allylic series 443
   C. Acetylenic series 445
   D. Cyclenic equivalents of the phenyl ring 447
IV. Effects of Halogenation 448
   A. The importance of the halogens in the structure–activity relationship 448
   B. Usefulness of the halogens and of cognate functions 451
V. Effects of Hydroxylation 452
   A. Effects on solubility 453
   B. Effects on the ligand–receptor interaction 453
   C. Hydroxylation and metabolism 453
VI. Effects of Thiols and Other Sulfur-Containing Groups 454
   A. Drugs containing thiol 454
   B. Drugs containing oxidized sulfides 454
   C. Drugs containing thiocyanate or thiourea 454
VII. Acidic Functions 456
   A. Effects on solubility 456
   B. Effects on biological activity 457
VIII. Basic Groups 458
IX. Attachment of Additional Binding Sites 459
   A. To increase lipophilicity 459
   B. To achieve additional interactions 459
References 460

21. The Role of Functional Groups in Drug–Receptor Interactions 464
   Laurent Schaeffer
   I. Introduction 464
   II. General Principles 464
   III. The Importance of the Electrostatic and Steric Match Between Drug and Receptor 465
      A. Electrostatic interactions 465
      B. Steric interactions 471
      C. Enthalpy/entropy compensation 472
   IV. The Strengths of Functional Group Contributions to Drug–Receptor Interactions 473
      A. Measuring functional group contributions 473
      B. The methyl group and other nonpolar substituents 475
      C. The hydroxyl group and other hydrogen-bond forming substituents 476
      D. Acidic and basic substituents 476
      E. Practical applications for the medicinal chemist 476
      F. Ligand efficiency 478
   V. Cooperative binding 478
References 479

22. Compound Properties and Drug Quality 481
   Christopher A. Lipinski
   I. Introduction 481
   II. Combinatorial Libraries 482
      A. Library design for HTS screens 482
      B. Experimental synthesis success rate 483
      C. Poor solubility and library design 483
      D. Importance of the synthesis rate-determining step 483
      E. If protocol development is rate determining 484
      F. Poor ADME properties – business aspects 484
23. Quantitative Approaches to Structure–Activity Relationships

Han van de Waterbeemd and Sally Rose

I. Introduction to QSAR 491
II. Brief History and Outlook 492
III. QSAR Methodology 493
   A. Descriptors 493
   B. Methods for building predictive models 496
   C. Global and local models, and consensus modeling 503
   D. Time-series behavior and autoQSAR 503
   E. Experimental design 504
   F. Inverse QSAR and multi-objective optimization 505
IV. Practical Applications 505
   A. Limitations and appropriate use 505
   B. Examples 506
   C. Library design, compound acquisition and profiling 508
   D. HTS analysis 509
   E. Software 509
References 510

Part V Spatial Organization, Receptor Mapping and Molecular Modeling

Section Editor: David J. Triggle

24. Overview: The Search for Biologically Useful Chemical Space

David J. Triggle

I. Introduction 517
II. How Big is Chemical Space? 518
III. Biological Space is Extremely Small 518
IV. Limited Biological Space as an Effective Biological Strategy 519
References 520
25. **Pharmacological Space**  
*Andrew L. Hopkins*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. What is Pharmacological Space?</td>
<td>521</td>
</tr>
<tr>
<td>II. Chemical Space</td>
<td>521</td>
</tr>
<tr>
<td>A. Drug-like space</td>
<td>522</td>
</tr>
<tr>
<td>III. Target Space</td>
<td>524</td>
</tr>
<tr>
<td>A. Druggability</td>
<td>525</td>
</tr>
<tr>
<td>B. Structure-based druggability</td>
<td>526</td>
</tr>
<tr>
<td>C. Degrees of druggability</td>
<td>527</td>
</tr>
<tr>
<td>D. Druggable genome</td>
<td>529</td>
</tr>
<tr>
<td>VI. Conclusions</td>
<td>531</td>
</tr>
</tbody>
</table>

Acknowledgments  
References  

26. **Optical Isomerism in Drugs**  
*Camille G. Wermuth*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>533</td>
</tr>
<tr>
<td>II. Experimental Facts and Their Interpretation</td>
<td>533</td>
</tr>
<tr>
<td>A. Stereoselectivity in biologically active compounds</td>
<td>533</td>
</tr>
<tr>
<td>B. The three-point contact model</td>
<td>535</td>
</tr>
<tr>
<td>C. Diastereoisomers</td>
<td>537</td>
</tr>
<tr>
<td>D. Stereoselectivity ratios</td>
<td>537</td>
</tr>
<tr>
<td>E. Pfeiffer's rule</td>
<td>538</td>
</tr>
<tr>
<td>III. Optical Isomerism and Pharmacodynamic Aspects</td>
<td>538</td>
</tr>
<tr>
<td>A. Differences in potency and antagonism between two enantiomers</td>
<td>538</td>
</tr>
<tr>
<td>B. Differences in the pharmacological profile of two enantiomers</td>
<td>539</td>
</tr>
<tr>
<td>IV. Optical Isomerism and Pharmacokinetic Effects</td>
<td>539</td>
</tr>
<tr>
<td>A. Isomer effects on absorption and distribution</td>
<td>540</td>
</tr>
<tr>
<td>B. Isomer effects on metabolism</td>
<td>540</td>
</tr>
<tr>
<td>C. Isomer effects on uptake</td>
<td>541</td>
</tr>
<tr>
<td>D. Isomer effects on excretion</td>
<td>541</td>
</tr>
<tr>
<td>V. Practical Considerations</td>
<td>541</td>
</tr>
<tr>
<td>A. Racemates or enantiomers?</td>
<td>541</td>
</tr>
<tr>
<td>B. The distomer counteracts the eutomer</td>
<td>542</td>
</tr>
<tr>
<td>C. Racemic switches</td>
<td>542</td>
</tr>
<tr>
<td>D. The distomer is metabolized to unwanted or toxic products</td>
<td>542</td>
</tr>
<tr>
<td>E. Deletion of the chiral center</td>
<td>543</td>
</tr>
<tr>
<td>F. Usefulness of racemic mixtures</td>
<td>543</td>
</tr>
</tbody>
</table>

References  

27. **Multi-Target Drugs: Strategies and Challenges for Medicinal Chemists**  
*Richard Morphy and Z. Rankovic*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>549</td>
</tr>
<tr>
<td>II. Strategies for Lead Generation</td>
<td>551</td>
</tr>
<tr>
<td>III. Main Areas of Focus in DML Discovery (1990–2005)</td>
<td>553</td>
</tr>
<tr>
<td>A. SERT-plus DMLs for depression</td>
<td>554</td>
</tr>
<tr>
<td>B. Dopamine D2-plus DMLs for schizophrenia</td>
<td>555</td>
</tr>
<tr>
<td>C. DMLs targeting the angiotensin system for hypertension</td>
<td>555</td>
</tr>
<tr>
<td>D. Histamine H1-plus DMLs for allergies</td>
<td>558</td>
</tr>
<tr>
<td>E. AChE-based DMLs for Alzheimer’s disease</td>
<td>559</td>
</tr>
<tr>
<td>F. PPAR-based DMLs for metabolic disease</td>
<td>560</td>
</tr>
<tr>
<td>G. DMLs that inhibit multiple kinases for treating cancer</td>
<td>560</td>
</tr>
</tbody>
</table>
28. Pharmacophore Identification and Pseudo-Receptor Modeling
Wolfgang Sippl

I. Introduction
A. Historical background
B. Definitions
C. Importance of the pharmacophore concept
D. Application of pharmacophores

II. Methodology
A. Pharmacophore modeling

III. Advanced approaches
A. Structure-based pharmacophores
B. Pseudo-receptor models

IV. Application study
A. Pharmacophore-based screening for novel histamine H3-receptor antagonists
B. Pharmacophore determination process
C. Pharmacophore-based screening of compound libraries

V. Conclusions

References

29. 3D Quantitative Structure–Property Relationships
Thierry Langer and Sharon D. Bryant

I. Introduction

II. 3D QSAR Workflow

III. Calculation of 3D Molecular Field Descriptors

IV. Statistical Tools

V. Alignment Independent 3D QSAR Techniques

VI. Validation Of 3D QSAR Models

VII. Applications
A. 3D QSAR study on the structural requirements for inhibiting AChE
B. 3D QSAR as a tool to determine molecular similarity

IX. Conclusions and Future Directions

References

30. Protein Crystallography and Drug Discovery
Jean-Michel Rondeau and Herman Schreuder

I. Presentation

II. Historical Background
A. The early days of crystallography
B. The current state of the art
C. Past and present contributions to drug discovery

III. Examples
A. Aliskiren (Tekturna™, Rasilez™)
B. Nilotinib (Tasigna™)

IV. Basic Principles and Methods of Protein Crystallography
A. Crystallization
Part VI Chemical Modifications Influencing the Pharmacokinetic Properties
Section Editor: Richard B. Silverman

31. Physiological Aspects Determining the Pharmacokinetic Properties of Drugs
Koen Boussery, Frans M. Belpaire and Johan Van de Voorde

I. Introduction

II. Passage of Drugs Through Biological Barriers
A. Transcellular drug transport
B. Paracellular drug transport

III. Drug Absorption
A. Dosage form of the drug
B. GI motility and gastric emptying
C. GI permeability to the drug
D. Perfusion of the GI tract and the first-pass effect

IV. Drug Distribution
A. Plasma protein binding
B. Drug accumulation
C. The blood–brain barrier

V. Drug Elimination
A. Excretion
B. Biotransformation

VI. Some Pharmacokinetic Parameters and Terminology
A. Plasma concentration–time curve
B. Volume of distribution
C. Clearance
D. Elimination half-life ($T_{1/2}$)
E. Bioavailability

VII. Variability in Pharmacokinetics
A. Genetic factors
B. Age
C. Drug interactions
D. Disease state
E. Pregnancy

Bibliography

32. Biotransformation Reactions and their Enzymes
Bernard Testa

I. Introduction

II. Functionalization Reactions
A. Enzymes catalyzing functionalization reactions
B. Reactions of carbon oxidation and reduction
C. Oxidation and reduction of N- and S-containing moieties
D. Reactions of hydration and hydrolysis
III. Conjugation Reactions
   A. Introduction  664
   B. Methylation  665
   C. Sulfonation  665
   D. Glucuronidation  665
   E. Acetylation  667
   F. Conjugation with coenzyme A and subsequent reactions  668
   G. Conjugation reactions of glutathione  669

IV. Biological Factors Influencing Drug Metabolism  671
V. Concluding Remarks  672

References  672

33. Biotransformations Leading to Toxic Metabolites: Chemical Aspects  674
Anne-Christine Macherey and Patrick M. Dansette

I. Historical Background  674
II. Introduction  675
III. Reactions Involved in the Bioactivation Process  676
   A. Oxidation  676
   B. Oxidative stress  678
   C. Reduction  680
   D. Substitutions: hydrolysis and conjugation  682
   E. Eliminations  683
   F. Further biotransformations leading to the ultimate toxicant  683
IV. Examples of Metabolic Conversions Leading to Toxic Metabolites  685
   A. Acetaminophen  685
   B. Tienilic acid  687
   C. Halothane  688
   D. Valproic acid  690
   E. Troglitazone  691
V. Conclusion  693

References  694

34. Drug Transport Mechanisms and their Impact on the Disposition and Effects of Drugs  697
Jean-Michel Scherrmann

I. Introduction  697
II. Biology and Function of Transporters  698
   A. Modes of active transport  698
   B. Genes and classification  698
   C. Basic structure  699
   D. Distributions and properties of transporters in tissues  699
III. Transporters in Drug Disposition  702
   A. ABC transporters  702
   B. SLC transporters  703
IV. Roles of Transporters in Drug Pharmacokinetics, Pharmacodynamics and Toxicology  705
   A. Intestinal absorption  705
   B. Liver and hepatic clearance  706
   C. Blood barriers and tissue distribution  707
   D. Kidney and renal clearance  707
V. Conclusion  709

Acknowledgments  709

References  709
### Contents

| A. The determination and prediction of solubility | 750 |
| B. Ionization of drugs and the importance of $pK_a$ | 751 |

### III. Acids and Bases Used in Salt Formation

### IV. Early salt formation studies

| A. Choice of salt formers | 753 |
| B. Prediction of the pH of the salt in solution | 754 |
| C. Search for crystalline salts | 755 |

### V. Comparison of Different Crystalline Salts

| A. Melting point | 756 |
| B. Aqueous solubility | 756 |
| C. Common ion and indifferent electrolyte effects | 758 |
| D. Hygroscopicity | 758 |
| E. Solubility in co-solvents (water-miscible solvents) | 759 |
| F. Dissolution Rate | 759 |
| G. Particle size and crystal morphology | 760 |
| H. Polymorphism and pseudopolymorphism | 760 |
| I. Chemical stability | 761 |
| J. Other properties | 761 |

### VI. Implications of Salt Selection on Drug Dosage Forms

| A. Tablet products | 762 |
| B. Hard gelatine capsules | 763 |
| C. Parenteral solutions | 763 |
| D. Oral solutions | 763 |
| E. Suspension formulations | 763 |
| F. MDI products | 764 |
| G. DPI products | 764 |
| H. Soft gelatine capsule formulations | 764 |
| I. Emulsions, creams and ointments | 764 |

### VII. Conclusion

References 765

---

38. Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties

**Camille G. Wermuth**

| I. Introduction | 767 |
| II. Solubilization Strategies | 768 |
| A. How will the solubilizing moiety be grafted? | 768 |
| B. Where will it be grafted? | 768 |
| C. What kind of solubilizing chain will be utilized? | 768 |

### III. Acidic Solubilizing Chains

| A. Direct introduction of acidic functions | 769 |
| B. Alkylation of OH and NH functions with acidic chains | 769 |
| C. Acylation of OH and NH functions with acidic chains | 770 |

### IV. Basic Solubilizing Chains

| A. Direct attachment of a basic residue | 775 |
| B. Biosisosteric exchange of a basic functionality | 776 |
| C. Development of a water-soluble produg of diazepam | 776 |
| D. Attachment of the solubilizing moiety to an alcoholic hydroxyl | 777 |
| E. Attachment of the solubilizing moiety to an acidic NH function | 779 |
| F. Attachment of the solubilizing moiety to a basic NH$_2$ function | 779 |
| G. Attachment of the solubilizing moiety to carboxylic acid functionalities | 780 |

### V. Non-ionizable Side Chains

| A. Glycolyl and glyceryl side chains | 780 |
| B. Polyethylene glycol derivatives | 781 |
| C. Glucosides and related compounds | 781 |
39. Drug Solubilization with Organic Solvents, or Using Micellar Solutions or Other Colloidal Dispersed Systems
Michael J. Bowker and P. Heinrich Stahl

I. Introduction 786
II. Factors Controlling Solubility and Absorption 788
   A. The nature of drug substances 788
   B. The polarity of the solvent system 788
III. Water–cosolvent systems 789
IV. Solubilization Mediated by Surfactants 793
   A. Emulsions and microemulsions 798
   B. Liposomes 802
VI. Nanoparticles and Other Nanocolloidal Technologies 803
VII. Drug Delivery and Clearance Mechanisms of Nanocolloids 806
VIII. Drug Delivery and Accumulation Using Colloidal Systems for the Treatment of Cancer 807
   A. Liposome formulations 807
   B. Formulations based on nanoparticles, microparticles and conjugated systems 808
IX. Modification of Drug Toxicity by Nanocolloidal Drug Delivery Systems 808

40. Improvement of Drug Properties by Cyclodextrins
Kaneto Uekama and Fumitoshi Hirayama

I. Introduction 813
II. Pharmaceutically Useful CyDs 813
   A. Physicochemical profiles of CyDs 814
   B. Biological profiles of CyDs 814
III. Improvement of Drug Properties 816
   A. Solubilization 817
   B. Stabilization in solution 818
   C. Control of solid properties 819
   D. Release control 821
   E. Enhancement of drug absorption 822
   F. Reduction of side-effects 824
   G. Use in peptide and protein drugs 826
   H. Combined use of CyDs with additives 829
IV. CyD-Based Site-Specific Drug Delivery 831
   A. Colon targeting 832
   B. Cell targeting 834
   C. Brain targeting 835
V. Conclusion 835

41. Chemical and Physicochemical Approaches to Solve Formulation Problems
Camille G. Wermuth

I. Introduction 841
II. Increasing Chemical Stability 841
III. Improved Formulation of Peptides and Proteins 844
IV. Dealing with Mesomorphic Crystalline Forms 845
V. Increasing the Melting Point 846
   A. Salt or complex formation 846
   B. Covalent derivatives 846
C. Introduction of symmetry

VI. Gastrointestinal Irritability and Painful Injections
   A. Gastrointestinal irritability
   B. Avoidance of painful injections

VII. Suppressing Undesirable Organoleptic Properties
   A. Odor
   B. Taste

References

Part VIII Development of New Drugs: Legal and Economic Aspects
Section Editor: Bryan G. Reuben

42. Discover a Drug Substance, Formulate and Develop It to a Product
   Bruno Galli and Bernard Faller
   I. Introduction
   II. Discover the Drug Substance
      A. Exploratory research (target finding)
      B. Early discovery program (lead finding)
      C. Mature discovery program (lead optimization)
      D. Research–development interface
      E. Learning experiences
   III. Defining Experimental Formulations, The Creative Phase
      A. Basic thoughts on oral formulation
      B. What is the purpose of a formulation?
      C. Suggested sequence of activities prior to start formulation
      D. Biopharmaceutical classification of compounds
      E. How do we proceed at a practical level?
      F. Which formulation principles are used?
   IV. Pharmaceutical Development in Industry
   V. Fixing The Quality And Develop The Product in A Regulated Environment

References

43. Drug Nomenclature
   R. G. Balocco Mattavelli, J.C. Dong, S. Lasseur and S. Kopp
   I. Introduction
   II. Trade Names and Nonproprietary Names
   III. Drug Nomenclature
      A. INNs for pharmaceutical substances
      B. Common names selected by the International Standards Organization (ISO)
   IV. Use and Protection of Nonproprietary Names
      A. Use of nonproprietary names
      B. Protection of nonproprietary names
   V. Summary

References

Annex

44. Legal Aspects of Product Protection: What a Medicinal Chemist Should Know about Patent Protection
   Maria Souleau
   I. Introduction
      A. History of the patent-system prior to 1883
      B. Main conventions and treaties
II. Definition of A Patent – Patent Rights 882
III. Kind of Inventions 882
IV. Subjects of Patents: Basic and Formal Requirements for Filing a Patent 882
   A. Basic requirements 882
   B. Formal requirements 888
V. Lifetime of Patents 890
VI. Ownership of Patents 890
VII. Infringement of a Patent 890
VIII. Patents as a Source of Information 891
IX. Patenting in the Pharmaceutical Industries 891
X. Conclusion 892
References 892

45. The Consumption and Production of Pharmaceuticals 894
   Bryan G. Reuben

I. “Important” Drugs 895
   A. The top-earning drugs 895
   B. The most widely prescribed drugs 895
   C. National differences in prescribing 899
II. Sources of Drugs 902
   A. Vegetable sources 902
   B. Animal sources 902
   C. Biological sources 902
   D. Fermentation 903
   E. Chemical synthesis 903
III. Manufacture of Drugs 903
   A. Good manufacturing practice 904
   B. Plant design 904
   C. Formulation and packaging–sterile products 905
   D. Choice of reagents 906
   E. “Green” chemistry 906
   F. Downstream processing 907
   G. Outsourcing 907
IV. Social and Economic Factors 909
   A. Pattern and cost of innovation 909
   B. Patents 910
   C. Orphan drugs 911
   D. Generic pharmaceuticals 912
   E. Parallel trade 914
   F. Cost containment measures 914
   G. Pharmacoeconomics 916
V. The Future of the Pharmaceutical Industry 918
   A. Trends in pharmaceuticals 919
   B. Conclusion 920
References 920

Index 923
Camille-Georges Wermuth
PhD, Prof. and Founder of Prestwick Chemical, was Professor of Organic Chemistry and Medicinal Chemistry at the Faculty of Pharmacy, Louis Pasteur University, Strasbourg, France from 1969 to 2002. He became interested in Medicinal Chemistry during his two years of military service in the French Navy at the Centre d’Etudes Physiologiques Appliquées à la Marine” in Toulon. During this time he worked under the supervision of Dr Henri Laborit, the scientist who invented artificial hibernation and discovered chlorpromazine.

Professor Wermuth’s main research themes focus on the chemistry and the pharmacology of pyridazine derivatives. The 3-aminopyrazidine pharmacophore, in particular, allowed him to accede to an impressive variety of biological activities, including antidepressant and anticonvulsant molecules; inhibitors of enzymes such as mono-amine-oxidases, phosphodiesterases and acetylcholinesterase; ligands for neuro-receptors: GABA-A receptor antagonists, serotonin 5-HT3 receptor antagonists, dopaminergic and muscarinic agonists. More recently, in collaboration with the scientists of the Sanofi Company, he developed potent antagonists of the 41 amino-acid neuropeptide CRF (corticotrophin-releasing factor) which regulates the release of ACTH and thus the synthesis of corticoids in the adrenal glands.

Professor Wermuth has also, in collaboration with Professor Jean-Charles Schwartz and Doctor Pierre Sokoloff (INSERM, Paris), developed selective ligands of the newly discovered dopamine D3 receptor. After a three year exploratory phase, this research has led to nanomolar partial agonists which may prove useful in the treatment of the cocaine-withdrawal syndrome.

Besides about 300 scientific papers and about 80 patents, Professor Wermuth is co-author or editor of several books including: Pharmacologie Moléculaire, Masson & Cie, Paris; Médicaments Organiques de Synthèse, Masson & Cie, Paris; Medicinal Chemistry for the Twenty-first Century, Blackwell Scientific Publications, Oxford; Trends in QSAR and Molecular Modeling, ESCOM, Leyden, two editions of The Practice of Medicinal Chemistry, Academic Press, London and The Handbook of Pharmaceutical Salts, Properties Selection and Use, Wiley-VCH.

Professor Wermuth was awarded the Charles Mentzer Prize of the Société Française de Chimie Thérapeutique in 1984, the Léon Velluz Prize of the French Academy of Science in 1995, the Prix de l'Ordre des Pharmaciens 1998 by the French Academy of Pharmacy and the Carl Mannich Prize of the German Pharmaceutical Society in 2000. He is Corresponding Member of the German Pharmaceutical Society and was nominated Commandeur des Palmes Académiques in 1995. He has been President of the Medicinal Chemistry Section of the International Union of Pure and Applied Chemistry (IUPAC) from 1988 to 1992 and from January 1998 to January 2000 was President of the IUPAC Division on Chemistry and Human Health.
Michael J. Bowker studied chemistry and received his doctorate in Organic Chemistry from the University of Leeds, UK. After 5 years working for a multinational polymer company, he moved to May & Baker Ltd., a UK subsidiary of Rhône-Poulenc Santé (now Sanofi-Aventis). He was a Director of Analytical Chemistry for about 15 years and, more recently, Director of Preformulation at Aventis Pharma Ltd. He has been intimately involved in preformulation and solid-state activities, on a worldwide basis for more than 15 years. He has published several research papers and one chapter for a book on pharmaceutical salts and is currently a Director of M. J. Bowker Consulting Limited, a small company undertaking consultancy in salt selection, polymorph selection and pharmaceutical preformulation.

Hugo Kubinyi is a Medicinal Chemist with 35 years of industrial experience in drug design, molecular modelling, protein crystallography and combinatorial chemistry, in Knoll and BASF AG, Ludwigshafen. He is a Professor of Pharmaceutical Chemistry at the University of Heidelberg, former Chair of The QSAR and Modelling Society and IUPAC Fellow. From his scientific work resulted more than 100 publications and seven books on QSAR, drug design, chemogenomics, and drug discovery technologies.

John R. Proudfoot received his Ph.D. from University College Dublin, Ireland in 1981 working with Professor Dervilla Donnelly. He completed postdoctoral studies with Professor Carl Djerassi at Stanford University and Professor John Cashman at the University of California San Francisco. In 1987, he joined Boehringer Ingelheim and is presently a Distinguished Scientist in the medicinal chemistry department.

Bryan G. Reuben is Professor Emeritus of Chemical Technology at London South Bank University. He has written widely on the technology and economics of the chemical and pharmaceutical industries. His most recent experimental work was on hydrogen-deuterium exchange in protonated peptides and on the downstream processing of nisin.

Richard B. Silverman is the John Evans Professor of Chemistry at Northwestern University. He has published 240 research articles, holds 38 domestic and foreign patents, has written four books, and is the inventor of Lyrica™ (pregabalin), marketed worldwide by Pfizer for refractory epilepsy, neuropathic pain, fibromyalgia, and (in Europe) for generalized anxiety disorder.

David J. Triggle is a SUNY Distinguished Professor and the University Professor State University of New York at Buffalo. Educated in United Kingdom and Canada in physical and organic chemistry he has served a variety roles at Buffalo including Dean of the School of Pharmacy and University Provost. His work has been principally in the area of the chemical pharmacology of drug–receptor and drug–ion channel interactions. He is the author and editor of some 30 books and several hundred publications.

Han van de Waterbeemd studied organic and medicinal chemistry and got his PhD at the University of Leiden. After his academic years at the University of Lausanne with Bernard Testa he worked for 20 years in the pharmaceutical industry for Roche, Pfizer and AstraZeneca. His research interests are in optimizing compound quality using measured and predicted physicochemical and DMPK properties. He contributed to 145 research papers and book chapters, and (co-)edited 13 books.
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raffaella. G. Balocco Mattavelli</td>
<td>Manager of the International Nonproprietary Names Programme</td>
<td>20, av. Appia, CH-1211, Geneva 27</td>
</tr>
<tr>
<td>Paul L. Bartel</td>
<td>Myriad Genetics, Inc.</td>
<td>320 Wakara Way, Salt Lake City, UT 84108, USA</td>
</tr>
<tr>
<td>Patrick Bazzini</td>
<td>Prestwick Chemical Inc.</td>
<td>Boulevard Gonthier, d’Andermarch, Illkirch, France</td>
</tr>
<tr>
<td>Frans M. Belpaire</td>
<td>Heymans Institute for Pharmacology</td>
<td>Jeroom Duquesnoylaan 37, 9051 Gent, Belgium</td>
</tr>
<tr>
<td>Koen Boussery</td>
<td>Laboratory of Medical Biochemistry and Clinical Analysis</td>
<td>Gent University, Harelbekestraat 72, 9000 Gent, Belgium</td>
</tr>
<tr>
<td>Michael J. Bowker</td>
<td>M.J. Bowker Consulting Ltd.</td>
<td>36, Burses Way, Hutton, Brentwood, Essex CM13 2PS, UK</td>
</tr>
<tr>
<td>Sharon D. Bryant</td>
<td>Medicinal Chemistry Group</td>
<td>45, Rue des Saints Pères, F-75270 Paris Cedex 06, France</td>
</tr>
<tr>
<td>David Cavalla</td>
<td>Arachnoua</td>
<td>St. John’s Innovation Centre, Cambridge CB4 4WS, UK</td>
</tr>
<tr>
<td>François Chast</td>
<td>Pharmacy, Pharmacology, Toxicology Department</td>
<td>Hôtel-Dieu, 1, Place du Parvis Notre-Dame, 75004 Paris, France</td>
</tr>
<tr>
<td>Paola Ciapetti</td>
<td>Head of Medicinal Chemistry</td>
<td>Boulevard Sébastien Brant BP 30170, F-67405 Illkirch Cedex, France</td>
</tr>
<tr>
<td>Jean-Marie Contreras</td>
<td>Prestwick Chemical Inc.</td>
<td>Boulevard Gonthier d’Andermarch, Illkirch, France</td>
</tr>
<tr>
<td>Gordon M. Cragg</td>
<td>Natural Products Branch</td>
<td>1003 W 7th Street, Suite 206, Frederick, MD 21701, USA</td>
</tr>
<tr>
<td>Patrick M. Dansette</td>
<td>Laboratoire de Chimie et Biochimie</td>
<td>Laboratoire de Chimie et Toxicologiques, Université PARIS Descartes, UMR 8601 – CNRS, 45, Rue des Saints Pères, F-75270 Paris Cedex 06, France</td>
</tr>
</tbody>
</table>
Ji-Cui Dong  
International Nonproprietary Names Programme  
Quality Assurance & Safety: Medicines  
World Health Organization  
20, av. Appia  
CH-1211, Geneva 27

Bernard Faller  
Novartis Pharma AG  
Werk Klybeck  
Klybeckstrasse 141  
WKL-122.P.33  
CH-4057 Basel  
Switzerland

Bennett T. Farmer  
Boehringer Ingelheim Pharmaceuticals, Inc.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877  
USA

Bruno Galli  
Novartis Pharma AG  
TRD-PTM WSJ-340-451  
Lichtstrasse 35  
CH-4056 Basel  
Switzerland

Jean-Pierre Gies  
Université Louis Pasteur  
Faculté de Pharmacie  
Equipe de Signalisation Cellulaire  
74, Route du Rhin  
67401 Illkirch-Cedex,  
France

Bruno Giethlen  
Prestwick Chemical Inc.  
Boulevard Gonthier d’Andernach  
67400 Illkirch  
France

Fumitoshi Hirayama  
Faculty of Pharmaceutical Sciences  
Sojo University  
4-22-1 Ikeda  
Kumamoto 860-0082  
Japan

Adrian N. Hobden  
Myriad Genetics, Inc.  
320 Wakara Way  
Salt Lake City, UT 84108  
USA

Andrew L. Hopkins  
Division of Biological Chemistry and Drug Discovery  
College of Life Sciences  
University of Dundee  
Dundee  
Scotland DD1 5EH  
UK

Peter Imming  
Institut für Pharmazie  
Martin-Luther-Universitaet Halle-wittenberg Wolfgang-Langenbeck-Str. 4  
06120 Halle (Saale) Germany

Paul F. Jackson  
Johnson & Johnson  
Pharmaceutical R&D, L.L.C.  
Welsh McKean Roads  
P.O. Box 776  
Spring House, PA 19477  
USA

David G. I. Kingston  
Virginia Polytechnic Institute & State University  
Department of Chemistry, M/C 0212  
3111 Hahn Hall  
West Campus Drive  
Blacksburg, VA 24061  
USA

Sabine Kopp  
Medicines Quality Assurance Programme  
Quality Assurance & Safety: Medicines  
World Health Organization  
20, av. Appia  
CH-1211 Geneva 27

Hugo Kubinyi  
Donnersbergstrasse 9  
67256 Weisenheim am Sand  
Germany

Kamal Kumar  
Max Planck Institute of Molecular Physiology  
Otto-Hahn-Str. 11  
D-44227 Dortmund  
Germany

Yves Landry  
Université Louis Pasteur  
Faculté de Pharmacie  
Equipe de Signalisation Cellulaire  
74, Route du Rhin  
67401 Illkirch-Cedex,  
France
Contributors

Thierry Langer
Inte:Ligan GmbH
Clemens Maria Hofbauer-G.6
2344 Maria Enzersdorf
Austria

Institute of Pharmacy
University of Innsbruck
Innrain 52
6020 Innsbruck
Austria

Sophie Lasseur
International Nonproprietary Names Programme
Quality Assurance & Safety: Medicines
World Health Organization
20, av. Appia
CH-1211, Geneva 27

Christopher A. Lipinski
Melior Discovery
10 Conshire Drive
Waterford, CT 06385-4122
USA

Anne-Christine Macherey
Unité de Prévention du Risque Chimique
UPS 831–Bat.11
CNRS
Avenue de la Terrasse
F-91198 Gif sur Yvette Cedex
France

André Mann
Département de Pharmacochimie de la Communication Cellulaire
UMR 7175 LC 1 ULP/CNRS
Faculté de Pharmacie
74 route du Rhin
67401 Illkirch
France

Christophe Morice
Prestwick Chemical Inc.
Boulevard Gonthier
d’Andermack
67400 Illkirch
France

Richard Morphy
Organon Laboratories Ltd.
A part of the Schering Plough Corporation
Newhouse
Lanarkshire
Scotland ML1 5SH
UK

David J. Newman
Natural Products Branch
National Cancer Institute
1003 W 7th Street, Suite 206
Frederick, MD 21701
USA

Jean-Pierre Nowicki
Sanofi-Aventis RD
31, Avenue Paul Vaillant-Couturier
92220 Bagneux
France

Alex Polinsky
Research Technologies
Pfizer Global Research and Development
620 Memorial Drive
Cambridge, MA 02138
USA

John R. Proudfoot
Boehringer Ingelheim Pharmaceuticals Inc.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
USA

Z. Rankovic
Organon Laboratories Ltd.
A part of the Schering Plough Corporation
Newhouse
Lanarkshire
Scotland ML1 5SH
UK

Allen B. Reitz
Johnson & Johnson
Pharmaceutical Research and Development, LLC
Welsh McKeans Rds.
Spring House, PA 19477
USA

Bryan G. Reuben
London South Bank University
24 Claverley Grove
London N3 2DH
UK

Jean-Michel Rondeau
Novartis Pharma AG
Novartis Institutes for BioMedical Research
WSJ-88.8.08A
CH-4056 Basel
Switzerland
Contributors

Sally Rose
Cresset BioMolecular Discovery Ltd
BioPark Hertfordshire
Broadwater Road
Welwyn Garden City
Herts., AL7 3AX
UK

Bernard Scatton
Sanofi-Aventis RD
31, Avenue Paul Vaillant-Couturier
92220 Bagneux
France

Laurent Schaeffer
Prestwick Chemical Inc.
Boulevard Gonthier
d’Andernach
67400 Illkirch
France

Jean-Michel Scherrmann
INSERM U 705; CNRS 7157
University Paris Descartes and Paris Diderot
Department of Pharmacokinetics Faculty of Pharmacy
4, avenue de l’Observatoire
75006 Paris
France

Herman Schreuder
Aventis Pharma Deutschland GmbH
Building G 6865A
D-65926 Frankfurt am Main
Germany

Brian C. Shook
Johnson & Johnson
Pharmaceutical R&D, L.L.C.
Welsh McKean Roads
P.O. Box 776
Spring House, PA 19477
USA

Richard B. Silverman
Department of Chemistry
Northwestern University
2145, Sheridon Road
Evanston, IL 60208-3113
USA

Wolfgang Sippl
Department of Pharmaceutical Chemistry
Martin-Luther-Universität Halle-Wittenberg
Wolfgang-Langenbeck-Str. 4
06120 Halle (Saale)
Germany

Maria Souleau
Sanofi-Aventis
20, Rue Raymond Aron
92160 Antony
France

P. Heinrich Stahl
Lerchenstrasse 28
79104 Freiburg im Breisgau
Germany

Bernard Testa
Service de Pharmacie, CHUV
Centre Hospitalier Universitaire Vaudois
Rue du Bugnon 46
CH-1011 Lausanne
Switzerland

David J Triggle
SUNY at Buffalo
School of Pharmaceutical Sciences
126 Cooke Hall
Buffalo, NY 14260
USA

Kaneto Uekama
Faculty of Pharmaceutical Sciences
Sojo University
4-22-1 Ikeda
Kumamoto 860-0082
Japan

Johan Van de Voorde
Ghent University
Vascular Research Unit
De Pintelaan 185 – Blok B
9000 Gent
Belgium

Han van de Waterbeemd
AstraZeneca
LG DECS, Global Compound Sciences
Alderley Park, 50S39
Macclesfield
Cheshire SK10 4TG
UK

Herbert Waldmann
Max Planck Institute of Molecular Physiology
Otto-Hahn-Str. 11
D-44227 Dortmund
Germany
Camille G. Wermuth
Prestwick Chemical Inc.
Boulevard Gonthier d’Andernach
67400 Illkirch
France

Kenton H. Zavitz
Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT 84108
USA

Stefan Wetzel
Max Planck Institute of Molecular Physiology
Otto-Hahn-Str. 11
D-44227 Dortmund
Germany
This page intentionally left blank
Preface to the First Edition

The role of chemistry in the manufacture of new drugs, and also of cosmetics and agrochemicals, is essential. It is doubtful, however, whether chemists have been properly trained to design and synthesize new drugs or other bioactive compounds. The majority of medicinal chemists working in the pharmaceutical industry are organic synthetic chemists with little or no background in medicinal chemistry who have to acquire the specific aspects of medicinal chemistry during their early years in the pharmaceutical industry. This book is precisely aimed to be their ‘bedside book’ at the beginning of their career.

After a concise introduction covering background subject matter, such as the definition and history of medicinal chemistry, the measurement of biological activities and the three main phases of drug activity, the second part of the book discusses the most appropriate approach to finding a new lead compound or an original working hypothesis. This most uncertain stage in the development of a new drug is nowadays characterized by high-throughput screening methods, synthesis of combinatorial libraries, data base mining and a return to natural product screening. The core of the book (Parts III to V) considers the optimization of the lead in terms of potency, selectivity, and safety. In ‘Primary Exploration of Structure-Activity Relationships’, the most common operational stratagems are discussed, allowing identification of the portions of the molecule that are important for potency. ‘Substituents and functions’ deals with the rapid and systematic optimization of the lead compound. ‘Spatial Organization, Receptor Mapping and Molecular Modelling’ considers the three-dimensional aspects of drug-receptor interactions, giving particular emphasis to the design of peptidomimetic drugs and to the control of the agonist-antagonist transition. Parts VI and VII concentrate on the definition of satisfactory drug-delivery conditions, i.e. means to ensure that the molecule reaches its target organ. Pharmacokinetic properties are improved through adequate chemical modifications, notably prodrug design, obtaining suitable water solubility (of utmost importance in medical practice) and improving organoleptic properties (and thus rendering the drug administration acceptable to the patient). Part VIII, ‘Development of New Drugs: Legal and Economic Aspects’, constitutes an important area in which chemists are almost wholly self taught following their entry into industry.

This book fills a gap in the available bibliography of medicinal chemistry texts. There is not, to the author-editor’s knowledge, any other current work in print which deals with the practical aspects of medicinal chemistry, from conception of molecules to their marketing. In this single volume, all the disparate bits of information which medicinal chemists gather over a career, and generally share by word-of-mouth with their colleagues, but which have never been organized and presented in coherent form in print, are brought together. Traditional approaches are not neglected and are illustrated by modern examples and, conversely, the most recent discovery and development technologies are presented and discussed by specialists. Therefore, The Practice of Medicinal Chemistry is exactly the type of book to be recommended as a text or as first reading to a synthetic chemist beginning a career in medicinal chemistry. And, even if primarily aimed at organic chemists entering into pharmaceutical research, all medicinal chemists will derive a great deal from reading the book.

The involvement of a large number of authors presents the risk of a certain lack of cohesiveness and of some overlaps, especially as each chapter is written as an autonomic piece of information. Such a situation was anticipated and accepted, especially for a first edition. It can be defended because each contributor is an expert in his/her field and many of them are ‘heavyweights’ in medicinal chemistry. In editing the book I have tried to ensure a balanced content and a more-or-less consistent style. However, the temptation to influence the personal views of the authors has been resisted. On the contrary, my objective was to combine a plurality of opinions, and to present and discuss a given topic from different angles. Such as it is, this first edition can still be improved and I am grateful in advance to all colleagues for comments and suggestions for future editions.

Special care has been taken to give complete references and, in general, each compound described has been identified by at least one reference. For compounds for which no specific literature indication is given, the reader is referred to the Merck Index.

The cover picture of the book is a reproduction of a copperplate engraving designed for me by the late Charles Gutknecht, who was my secondary school chemistry teacher in Mulhouse. It represents an extract of Brueghel’s engraving The alchemist ruining his family in pursuing his chimera, surmounted by the aquarius symbol. Represented on the left-hand side is my lucky charm caster oil plant (Ricinus communis L., Euphorbiaceae), which was the starting point of the pyridazine chemistry in my laboratory. The historical cascade of events was as follows: cracking of caster oil produces n-heptanal and aldolization of
n-heptanal – and, more generally, of any enolisable aldehyde or ketone – with pyruvic acid leads to α-hydroxy-γ-ketonic acids. Finally, the condensation of these keto acids with hydrazine yields pyrodazones. Thus, all our present research on pyridazine derivatives originates from my schoolboy chemistry, when I prepared in my home in Mulhouse n-heptanal and undecylenic acid by cracking caster oil!

Preparing this book was a collective adventure and I am most grateful to all authors for their cooperation and for the time and the effort they spent to write their respective contributions. I appreciate also their patience, especially as the editing process took much more time than initially expected.

I am very grateful to Brad Anderson (University of Utah, Salt Lake city), Jean-Jacques André (Marion Merrell Dow, Strasbourg), Richard Baker (Eli Lilly, Erl Wood, UK), Thomas C. Jones (Sandoz, Basle), Isabelle Morin (Servier, Paris), Bryan Reuben (London South Bank University) and John Topliss (University of Michigan, Ann Arbor) for their invaluable assistance, comments and contributions.

My thanks go also to the editorial staff of Academic Press in London, Particularly to Susan Lord, Nicola Linton and Fran Kingston, to the two copy editors Len Cegielka and Peter Cross, and finally, to the two secretaries of our laboratory, François Herth and Marylse Wernert.

Last but not least, I want to thank my wife Renée for all her encouragement and for sacrificing evenings and Saturday family life over the past year and a half, to allow me to sit before my computer for about 2500 hours!

Camille G. Wermuth
Preface to the Second Edition

Like the first edition of _The Practice of Medicinal Chemistry_ (nicknamed ‘The Bible’ by medicinal chemists) the second edition is intended primarily for organic chemists beginning a career in drug research. Furthermore, it is a valuable reference source for academic, as well as industrial, medicinal chemists. The general philosophy of the book is to complete the biological progress – Intellectualization at the level of function using the chemical progress Intellectualization at the level of structure (Professor Samuel J. Danishefsky, _Studies in the chemistry and biology of the epothilones and eleutherobins_, Conference given at the XXXIVémes Rencontres Internationales de Chimie Thérapeutique, Faculté de Pharmacie, Nantes, 8–10 July, 1998).

The recent results from genomic research have allowed for the identification of a great number of new targets, corresponding to hitherto unknown receptors or to new subtypes of already existing receptors. The massive use of combinatorial chemistry, associated with high throughput screening technologies, has identified thousands of hits for these targets. The present challenge is to develop these hits into usable and useful drug candidates. This book is, therefore, particularly timely as it covers abundantly the subject of drug optimization.

The new edition of the book has been updated, expanded and refocused to reflect developments over the nine years since the first edition was published. Experts in the field have provided personal accounts of both traditional methodologies, and the newest discovery and development technologies, giving us an insight into diverse aspects of medicinal chemistry, usually only gained from years of practical experience.

Like the previous edition, this edition includes a concise introduction covering the definition and history of medicinal chemistry, the measurement of biological activities and the three main phases of drug activity. This is followed by detailed discussions on the discovery of new lead compounds including automated, high throughput screening techniques, combinatorial chemistry and the use of the internet, all of which serve to reduce pre-clinical development times and, thus, the cost of drugs. Further chapters discuss the optimization of lead compounds in terms of potency, selectivity, and safety; the contribution of genomics; molecular biology and X-ray crystallization to drug discovery and development, including the design of peptide-mimetic drugs; and the development of drug-delivery systems, including organ targeting and the preparation of pharmaceutically acceptable salts. The final section covers legal and economic aspects of drug discovery and production, including drug sources, good manufacturing practices, drug nomenclature, patent protection, social-economic implications and the future of the pharmaceutical industry.

I am deeply indebted to all co-authors for their cooperation, for the time they spent writing their respective contributions and for their patience during the editing process. I am very grateful to Didier Rognan, Paola Ciapetti, Bruno Giethlen, Annie Marcincal, Marie-Louise Jung, Jean-Marie Contreras and Patrick Bazzini for their helpful comments.

My thanks go also to the editorial staff of _Academic Press_ in London, particularly to Margaret Macdonald and Jacqueline Read. Last but not least, I want to express my gratitude to my wife Renée for all her encouragements and for her comprehensiveness.

_Camille G. Wermuth_
This page intentionally left blank
Like the preceding editions of this book, this third edition treats of the essential elements of medicinal chemistry in a unique volume. It provides a practical overview of the daily problems facing medicinal chemists, from the conception of new molecules through to the production of new drugs and their legal/economic implications. This edition has been updated, expanded and refocused to reflect developments in the past 5 years, including 11 new chapters on topics such as hit identification methodologies and cheminformatics. More than 50 experts in the field from eight different countries, who have benefited from years of practical experience, give personal accounts of both traditional methodologies and the newest discovery and development technologies, providing readers with an insight into medicinal chemistry.

A major change in comparison to the previous editions was the decision to alleviate my editorial burden in sharing it with seven section editors, each being responsible for one of the eight sections of the book. I highly appreciated their positive and efficacious collaboration and express them my warmest thanks (in the alphabetical order) to Michael Bowker, Hugo Kubinyi, John Proudfoot, Bryan Reuben, Richard Silverman, David Triggie and Han van de Waterbeemd.

Another change was the decision taken by Elsevier/Academic Press to publish the book in full colors thus rendering it more pleasant and user-friendly. I take this occasion to thank Keri Witman, Pat Gonzales, Kirsten Funk and Renske van Dijk for having successfully ensured the editorial development of the book. Taking into account that we had to work with a cohort of about 50 authors, each of them having his personality, his original approach and his main busy professional live, this was not an easy task. I am deeply indebted to my assistant Odile Blin for the way she had mastered, efficiently and with friendliness, all the secretarial work and particularly the contacts with the different authors and with the Elsevier development editors. As for the earlier editions, I also want to express my gratitude to my wife Renée and my daughters Delphine, Joëlle and Séverine for all their encouragements and for sacrificing many hours of family life in order to leave me enough free time to edit this new version of the “Medicinal Chemist’s Bible.”

My final thoughts go to the future readers of the book, and especially to the newcomers in Medicinal Chemistry having the curiosity to read the preface. I cannot resist giving them some advice for doing good science.

First of all, be open-minded and original. As Schopenhauer noted, the task of the creative mind is “not so much to see what no one has seen yet; but to think what nobody has thought yet, about what everyone sees.” A wonderful illustration is found in Peter Hesse’s cartoon below.

Second, always keep in mind that the object of Medicinal Chemistry is to synthesize new drugs useful for suffering patients. Like many scientists, medicinal chemists, have to navigate between two tempting reefs. On one side they should avoid doing “NAAR”: non-applicable applied research, on the other side they may be attracted by “NFBR”: non-fundamental basic search.”

Third, convinced as they may be that the neighbors grass is always greener, they may be attracted to start their research in using as a hit a recently published competitor’s product. In fact, the published compound may exhibit only a weak activity, therefore be very careful when starting a new program and never forget that the worst thing a medicinal chemist can do is to prepare a me-too of an inactive compound!

Camille G. Wermuth
General Aspects of Medicinal Chemistry

Hugo Kubinyi

Section Editor
A History of Drug Discovery

From first steps of chemistry to achievements in molecular pharmacology

François Chast

I. INTRODUCTION
   A. The renewal of chemistry
   B. The dawn of the organic chemistry crosses the birth of biology

II. TWO HUNDRED YEARS OF DRUG DISCOVERIES
   A. Pain killers: best-sellers and controversies
   B. Giving back the heart its youth

C. Fight against microbes and viruses
D. Drugs for immunosuppression
E. Contribution of chemists to the fight against cancer
F. Drugs for endocrine disorders
G. Anti-acid drugs
H. Lipid lowering drugs
I. From neurotransmitters to receptors
J. Drugs of the mind

III. CONSIDERATIONS ON RECENT TRENDS IN DRUG DISCOVERY
A. From genetics to DNA technology
B. Hopes and limits for drug hunting

REFERENCES

Le médicament place l’organisme dans des conditions particulières qui en modifient heureusement les procédés physiques et chimiques lorsqu’ils ont été troublés.

Claude Bernard

During more than 2,000 years, Hippocratic medical tradition weighed on the development of a modern medicine and a renewed approach of the treatment of diseases. The basis for the use of drugs remained founded on empirical theories linked to the equilibrium of body’s “humors” consisting in sanguine, melancholic, phlegmatic and choleric. Health and disease were seen as a question of balance or imbalance with foods and herbs classified according to their ability to affect natural homeostasis. Later, during the Middle Ages, Muslim world made significant contributions to medicine and a major medical advance was the founding of many hospitals and university medical schools.

Before the 1800s, pharmacy remained an empiric science, guided by traditional medicine, inherited from “Ancients.” Numerous drugs, most of them being prepared with plant extracts, (Figure 1.1) sometimes efficacious, were available. But none of them could respond to a chemical definition of what we call today a drug, except drugs coming from mineral reign.

The technology of making drugs was crude at best: tinctures, poultices, soups, and infusions were made with water- or alcohol-based extracts of freshly ground or dried herbs or animal products such as bone, fat, or even pearls, and sometimes from minerals best left in the ground.¹

The objective of this first chapter is to offer a presentation of the fabulous history of drug discoveries, from traditional pharmacy emerged from ethnomedicine, till the recent

¹Leçons sur les Effets de Substances Médicamenteuses et Toxiques (1857) deuxième leçon (5 mars 1856), p.38: “Drugs place the body in particular conditions which modify fortunately the physical and chemical processes when they have been disturbed.”
experimental methodology. By formulating the principle of the conservation of mass, he gave a clear differentiation between elements and compounds, something so important for pharmaceutical chemistry. Few years later, Antoine François de Fourcroy, Louis Nicolas Vauquelin, Joseph Louis Proust, Jöns Jakob Berzelius, Louis-Joseph Gay-Lussac, and Humphrey Davy introduced new concepts in chemistry. Those scientists integrated the practical advancements of a new generation of experimenters. All these industrial innovations would have their own impact on other developments in industrial and then medicinal chemistry. At the turn of the 19th century, as the result of a scientific approach, drugs are becoming an industrial item. Claude Louis Berthollet began the industrial exploitation of chlorine (1785). Nicolas Leblanc prepared sodium hydroxide (1789) and then, bleach (1796). Davy performed electrolysis and distinguished between acids and anhydrides. Louis Jacques Thénard prepared hydrogen peroxide and Antoine Jérôme Balard discovered bromide (1826). The growing of therapeutic resources was mainly due to the mastery of chemical or physico-chemical principles proposed by Gay-Lussac and Justus Von Liebig. This chemists’ generation, by realizing all these discoveries, established the compost of the therapeutic discoveries of the 19th century. The constitution of chemistry as a scientific discipline found a new turn few decades later by crossing the road of biology which included revolutionary works of Claude Bernard, Rudolph Virchow, and Louis Pasteur. Besides these fundamental sciences, physiology, biochemistry, or microbiology were becoming natural tributaries of the out-break of pharmacology. Thus, rational treatments were about to be designed on the purpose of new knowledge in various clinical or fundamental fields. After a period characterized by extraction and purification from natural materials (mainly plants), drugs would be synthesized in chemical factories or prepared through biotechnology (fermentation or gene technology) after a rational research, design and development in research laboratories. Whereas the purpose was to isolate active molecules from plants during the first half of the 19th century, the birth of organic chemistry following charcoal and oil industries, progressively led chemists and pharmacists toward organic synthesis performed in what would be called “laboratory” a new concept created by this generation of scientists. Even when those laboratories hosted discoveries like active principles extracted from plants, progresses in drug compounding and packaging made irreversible industrialization processes. At the same time, the economical dimension of growing pharmaceutical industry transformed drugs as strategic items, mainly when it could interfere with military processes, for instance during colonial expeditions.

The “modern” word “pharmacology” became more and more often used by physicians after the works of François Magendie (Figure 1.2) in France or Oscar Schmiedeberg in Germany. Progressively a clear dichotomy took place between those two entities. Materia Medica considered drugs with a static and conservative view as for their